Stock Earnings

Question 1

Monte Rosa Therapeutics Inc'in temel mali tabloları nelerdir?

Accepted Answer

Son mali tabloya (Form-10K) göre, Monte Rosa Therapeutics Inc'in toplam varlıkları $438 olup, net loss $-72'dir.

Question 2

GLUE'ün temel finansal oranları nelerdir?

Accepted Answer

Monte Rosa Therapeutics Inc'in cari oranı 2.03, net kâr marjı -96, hisse başına satış $1.01'dir.

Question 3

Monte Rosa Therapeutics Inc'in geliri segment veya coğrafya bazında nasıl dağılıyor?

Accepted Answer

Monte Rosa Therapeutics Inc largest revenue segment is Novel Small Molecule Precision Medicines, at a revenue of 75,622,000 in the most earnings release.For geography, United States is the primary market for Monte Rosa Therapeutics Inc, at a revenue of 75,622,000.

Question 4

Monte Rosa Therapeutics Inc kârlı mı?

Accepted Answer

no, son mali tablolara göre Monte Rosa Therapeutics Inc'in net loss $-72'dir.

Question 5

Monte Rosa Therapeutics Inc'in herhangi bir yükümlülüğü var mı?

Accepted Answer

yes, Monte Rosa Therapeutics Inc'in yükümlülüğü 215'dir.

Question 6

Monte Rosa Therapeutics Inc'in tedavüldeki hisse sayısı kaçtır?

Accepted Answer

Monte Rosa Therapeutics Inc'in toplam tedavüldeki hisse sayısı 61.5'dir.

Breakdown	TTM	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Revenue	177	75	0	0	0	0
Revenue Growth (YoY)	3,440%	--	--	--	--	--
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	33	43	39	35	15	4
Research & Development	129	112	103	77	57	24
Operating Expenses	163	156	143	112	72	28
Other Non Operating Income (Expenses)	--	--	--	0	0	-7
Pretax Income	28	-70	-135	-108	-73	-35
Income Tax Expense	4	2	0	--	--	--
Net Income	24	-72	-135	-108	-73	-35
Net Income Growth	-118%	-47%	25%	48%	109%	400%
Shares Outstanding (Diluted)	82.18	73.91	51.39	47.23	46.54	44.49
Shares Change (YoY)	15%	44%	9%	1%	5%	0%
EPS (Diluted)	0.28	-0.98	-2.63	-2.3	-1.59	-0.81
EPS Growth	-115.99%	-63%	15%	45%	96%	376%
Free Cash Flow	23	38	-62	-105	-69	-26
Free Cash Flow Per Share	0.27	0.51	-1.2	-2.22	-1.48	-0.58
Gross Margin	--	--	--	--	--	--
Operating Margin	7.9%	-108%	0%	0%	0%	0%
Profit Margin	13.55%	-96%	0%	0%	0%	0%
Free Cash Flow Margin	12.99%	50.66%	0%	0%	0%	0%
EBITDA	22	-73	-137	-109	-70	-28
EBITDA Margin	12.42%	-97.33%	0%	0%	0%	0%
D&A For EBITDA	8	8	6	3	2	0
EBIT	14	-81	-143	-112	-72	-28
EBIT Margin	7.9%	-108%	0%	0%	0%	0%
Effective Tax Rate	14.28%	-2.85%	0%	--	--	--

Monte Rosa Therapeutics Inc (GLUE) Price

GLUE Stock Price Chart

GLUE Income

Follow-Up Questions